According to the in vitro data, the RFS probability is significantly increased in women carrying a LumA breast tumor (i.e., ERα-positive, PR-positive/negative, HER2-negative) expressing low GART mRNA levels (Figure 3E; Supplementary Table 4) while no significant differences in the survival rate depending on GART expression have been evidenced for women with LumB tumors (i.e., ERα-positive, PR-positive/negative, HER2-positive) (Figure 3F; Supplementary Table 4). This evidence concerns the gene PGR and breast neoplasm.